JAK Inhibitors for Alopecia Areata

Janus kinase inhibitors, commonly called JAK inhibitors, have fundamentally changed the treatment of severe alopecia areata. For decades, patients with extensive alopecia areata, alopecia totalis or alopecia universalis had few consistently effective systemic treatment options. Corticosteroids and other immunosuppressive medications were used with variable success, relapse was common, and long term treatment could be difficult.

That changed with the development of oral medications that interrupt specific immune signaling pathways involved in alopecia areata. In the United States, three oral JAK pathway treatments are currently FDA approved for severe alopecia areata: baricitinib, marketed as Olumiant, for adults; ritlecitinib, marketed as Litfulo, for adults and adolescents age 12 and older; and deuruxolitinib, marketed as Leqselvi, for adults.

These medications have produced substantial scalp hair regrowth in a meaningful proportion of patients with severe disease, including some who began treatment with nearly complete or complete scalp hair loss. Some patients also experience meaningful eyebrow and eyelash regrowth. JAK inhibitors are also systemic immune modifying medications with important potential risks, laboratory monitoring requirements, drug interactions and FDA boxed warnings.

They should therefore neither be portrayed as medications that patients should automatically fear nor as simple hair growth drugs. For appropriately selected patients with severe alopecia areata, they represent one of the most important advances in medical treatment of the disease.

What Is Alopecia Areata?

Alopecia areata is an autoimmune form of nonscarring hair loss in which immune activity develops around susceptible hair follicles and interrupts normal hair production. The disease can range from one or two small patches of scalp hair loss to extensive loss involving the scalp, eyebrows, eyelashes, beard and body hair. Complete or nearly complete scalp hair loss is called alopecia totalis, while extensive loss of scalp and body hair is called alopecia universalis.

The Severity of Alopecia Tool, or SALT score, is commonly used to quantify scalp involvement. A SALT score of 0 represents no scalp hair loss, while a SALT score of 100 represents complete scalp hair loss. The pivotal JAK inhibitor trials in severe alopecia areata generally enrolled patients with a SALT score of at least 50, meaning at least half of the scalp hair was absent.

That threshold is useful for understanding the clinical trial population, but disease severity should not be reduced to scalp percentage alone. Loss of eyebrows or eyelashes, rapidly progressive disease, nail involvement, duration of disease and psychological impact can all contribute to how severely alopecia areata affects a patient.

What Are JAK Inhibitors?

Janus kinases are intracellular enzymes that help transmit signals from immune system receptors into cells as part of the JAK STAT pathway. Several cytokines involved in alopecia areata rely on this signaling system. Interferon gamma and interleukin 15 are particularly important components of the immune activity that helps sustain the attack against the hair follicle.

JAK inhibitors interrupt portions of this signaling network. When the autoimmune activity is sufficiently reduced, follicles that remain capable of producing hair can return to productive growth.

This is fundamentally different from treating male or female pattern hair loss. JAK inhibitors do not primarily work by reducing DHT, blocking androgen receptors or stimulating follicles in the same way as minoxidil. They are treating an autoimmune disease.

Are All JAK Inhibitors the Same?

No. The term JAK inhibitor describes a broad category of medications, but the individual drugs are not interchangeable. Baricitinib primarily inhibits JAK1 and JAK2. Deuruxolitinib also inhibits JAK1 and JAK2. Ritlecitinib inhibits JAK3 and members of the TEC kinase family. They also differ in dosing, metabolism, age approvals, laboratory monitoring, drug interactions and other safety considerations.

These differences should not be translated into a simplistic ranking based on which medication blocks more kinases or appears more potent in a laboratory. Greater kinase inhibition does not automatically mean better hair regrowth or better treatment. The clinically important questions are whether the medication is appropriate for the individual patient, whether meaningful regrowth occurs, whether the response can be sustained and whether treatment can be used safely over the long term.

Which JAK Inhibitors Are FDA Approved for Alopecia Areata?

Three oral medications are currently FDA approved in the United States for severe alopecia areata.

Olumiant, Baricitinib

Baricitinib became the first FDA approved systemic treatment specifically for severe alopecia areata in adults. The recommended starting dose for alopecia areata is 2 mg once daily and can be increased to 4 mg once daily when response is inadequate. For patients beginning treatment with nearly complete or complete scalp hair loss, with or without substantial eyebrow or eyelash involvement, current prescribing information allows consideration of 4 mg once daily from the beginning.

Importantly, the FDA labeling does not assume that the highest dose should automatically be continued indefinitely. Once an adequate response has been achieved on 4 mg, the prescribing information recommends decreasing the dose to 2 mg once daily. That reflects an important treatment principle: the objective is adequate disease control with the lowest exposure that can reasonably maintain the benefit.

Litfulo, Ritlecitinib

Ritlecitinib is FDA approved for severe alopecia areata in adults and adolescents age 12 and older. The approved dose is 50 mg once daily, and it is currently the only FDA approved systemic JAK pathway treatment for alopecia areata that includes adolescents as young as 12.

That is an important advance for younger patients with severe disease, but age eligibility should not be confused with an automatic reason to prescribe systemic treatment. The extent and duration of hair loss, previous treatment, medical history, vaccination status, infection risk, psychological burden and ability to commit to long term monitoring all matter.

Leqselvi, Deuruxolitinib

Deuruxolitinib is FDA approved for adults with severe alopecia areata at a dose of 8 mg twice daily. It has an important pharmacogenetic issue that distinguishes it from the other currently approved medications because its metabolism depends substantially on the CYP2C9 enzyme.

Patients must be tested for CYP2C9 variants before treatment. Deuruxolitinib is contraindicated in CYP2C9 poor metabolizers because drug exposure can become substantially higher and potentially increase the risk of serious adverse effects. It is also contraindicated with moderate or strong CYP2C9 inhibitors.

Current prescribing information also notes an unusual practical limitation: an FDA cleared or FDA approved test specifically intended to direct Leqselvi use is not currently available. The required genetic evaluation therefore needs to be arranged and interpreted appropriately before treatment begins.

Are Other JAK Inhibitors Approved Outside the United States?

Yes, and the regulatory landscape is continuing to change.

Upadacitinib, marketed as Rinvoq, is now authorized in the European Union for severe alopecia areata in adults and adolescents age 12 and older. As of September 2026, it is not FDA approved for alopecia areata in the United States.

European indications for some other JAK inhibitors also differ from their U.S. indications. This is why consumers should be cautious when reading international treatment information online. A drug may be approved for alopecia areata in one jurisdiction and remain off label for the same condition in another.

How Effective Is Baricitinib?

Baricitinib was evaluated in two large Phase III trials known as BRAVE AA1 and BRAVE AA2 involving approximately 1,200 adults with severe alopecia areata and at least 50 percent scalp hair loss. The primary endpoint was achieving a SALT score of 20 or less, meaning at least 80 percent scalp hair coverage, after 36 weeks.

In BRAVE AA1, approximately 39 percent of patients receiving baricitinib 4 mg achieved this level of scalp coverage compared with approximately 23 percent receiving 2 mg and 6 percent receiving placebo. In BRAVE AA2, approximately 36 percent receiving 4 mg and 19 percent receiving 2 mg achieved the same endpoint compared with approximately 3 percent receiving placebo.

These results established that baricitinib can produce substantial regrowth in some patients with severe disease. They also demonstrate that response is far from universal. A medication can represent a major therapeutic advance without working for everyone.

Can Baricitinib Keep Working After the First Nine Months?

Yes. Continued treatment studies have shown that some patients who have not reached their best response at 36 weeks continue to improve with additional treatment.

Longer term follow up has also shown that patients who achieve substantial regrowth can often maintain it while treatment continues. Among patients who had reached a SALT score of 20 or less after one year and remained on the same baricitinib dose, approximately 89 percent of those receiving 4 mg and 84 percent of those receiving 2 mg still met that response threshold after approximately three years.

Those numbers apply to patients who had already responded to treatment and should not be interpreted as response rates for everyone who begins baricitinib. They do show that meaningful regrowth can be durable with continued treatment.

Can the Baricitinib Dose Be Reduced After Regrowth?

Sometimes, but dose reduction can involve a tradeoff.

In a long term study of patients who had responded to baricitinib 4 mg after one year, approximately 89 percent of those who remained on 4 mg maintained a SALT score of 20 or less through week 152, compared with approximately 59 percent of patients who were reduced to 2 mg.

Patients who had achieved particularly deep and sustained responses were more likely to maintain benefit after dose reduction.

This does not mean patients should remain on 4 mg indefinitely simply because it produced the initial response. The FDA labeling specifically recommends reducing to 2 mg once an adequate response has been achieved. It does mean that the hair should be monitored after dose reduction because some patients will lose part of their disease control.

The objective is the lowest effective sustainable exposure, not dose reduction at any cost.

How Effective Is Ritlecitinib?

The pivotal ALLEGRO Phase IIb and III program enrolled adults and adolescents age 12 and older with at least 50 percent scalp hair loss. Several dosing regimens were studied during development. At week 24, approximately 23 percent of patients receiving the FDA approved 50 mg daily regimen without a loading dose reached a SALT score of 20 or less compared with approximately 2 percent receiving placebo.

Some higher exposure development regimens produced somewhat higher early response rates, but the FDA approved regimen is 50 mg once daily.

Response continued to increase with longer treatment, and longer term analyses have shown that some patients continue improving after six months and even beyond one year. A lack of dramatic regrowth during the first few months does not necessarily establish that the medication will ultimately fail.

What Do the Longer Term Ritlecitinib Studies Show?

Longer follow up from the ALLEGRO clinical development program has demonstrated continued improvement over time. Among patients receiving the 50 mg regimen, approximately 61 percent of patients with available observations at month 24 had reached a SALT score of 20 or less.

However, when missing data were handled using a more conservative last observation carried forward analysis, the corresponding rate was approximately 46 percent.

Both analyses show that meaningful responses can continue to accumulate well beyond the first six months. The difference between those percentages also demonstrates why long term open label response rates should not be interpreted without understanding how missing data and continued study participation are handled.

Eyebrow and eyelash improvement was also documented in patients who had significant loss in those areas at baseline.

What Happens if Ritlecitinib Treatment Is Temporarily Interrupted?

A short interruption is not the same thing as permanently stopping treatment.

Current FDA prescribing information states that a temporary interruption of ritlecitinib lasting less than six weeks is not expected to result in significant loss of regrown scalp hair.

That is useful clinical information for patients who may need treatment temporarily interrupted because of illness, surgery or another medical issue. It should not be interpreted as evidence that the drug can be permanently discontinued without risk of relapse.

How Effective Is Deuruxolitinib?

Deuruxolitinib was evaluated in two major Phase III studies known as THRIVE AA1 and THRIVE AA2.

In THRIVE AA1, approximately 30 percent of adults receiving the now approved dose of 8 mg twice daily reached a SALT score of 20 or less at week 24 compared with less than 1 percent receiving placebo.

THRIVE AA2 produced a similar result, with approximately 33 percent of patients receiving 8 mg twice daily reaching the primary endpoint at week 24 compared with less than 1 percent receiving placebo.

A higher development dose produced somewhat greater response in clinical testing but is not the FDA approved regimen.

These trials demonstrate substantial efficacy in a meaningful subset of adults with severe alopecia areata. They do not establish that deuruxolitinib is superior to baricitinib or ritlecitinib.

Which JAK Inhibitor Works Best?

There is currently no high quality randomized head to head trial establishing that one of the three FDA approved medications is universally superior.

Comparing percentages from separate clinical trials can be misleading because the studies differed in duration, patient populations, disease severity, statistical methods and treatment protocols. The baricitinib pivotal trials used a 36 week primary endpoint, while the pivotal ritlecitinib and deuruxolitinib programs used 24 week endpoints.

Network meta analyses and other indirect comparisons have attempted to compare these medications, and some have ranked individual drugs differently depending on the endpoint and statistical method used. Those analyses can be useful research tools, but they are not substitutes for a randomized head to head clinical trial.

Treatment selection should instead consider the patient’s age, disease severity, medical history, previous treatment, laboratory findings, medication interactions, kidney and liver function, cardiovascular and thrombotic risk, cancer history, pregnancy potential and practical considerations such as once daily versus twice daily dosing.

Can JAK Inhibitors Regrow Eyebrows and Eyelashes?

They can. The major clinical development programs evaluated eyebrow and eyelash involvement in addition to scalp hair, and some patients with substantial eyebrow or eyelash loss experienced meaningful regrowth during treatment.

Response in these areas is not guaranteed, and scalp improvement does not always occur at the same pace as eyebrow or eyelash improvement. For patients with severe alopecia areata, recovery of eyebrows and eyelashes can be just as meaningful as scalp regrowth and should be documented when treatment response is evaluated.

Can JAK Inhibitors Regrow Hair in Alopecia Totalis or Alopecia Universalis?

Yes. Some patients with alopecia totalis or alopecia universalis have experienced substantial regrowth during JAK inhibitor therapy, and patients with nearly complete or complete scalp hair loss were included in the major clinical development programs.

Extremely severe and long standing disease can be more difficult to reverse. Analyses across several studies suggest that patients with less extensive disease or shorter current episodes may respond better or faster on average.

That should not be interpreted to mean that long standing alopecia universalis cannot respond. It means expectations should be individualized rather than using disease duration as an absolute eligibility rule.

How Long Does It Take for JAK Inhibitors to Work?

Hair regrowth generally takes months rather than weeks. Some patients begin noticing early regrowth within several months, while others require six months, one year or longer before achieving substantial scalp coverage.

The pivotal studies were designed around endpoints ranging from 24 to 36 weeks, and longer term studies have repeatedly shown additional improvement beyond those initial trial endpoints.

Treatment should therefore be evaluated using objective measurements and the trajectory of improvement rather than expecting a dramatic cosmetic response after several weeks. At the same time, treatment should not continue indefinitely without reassessment if there is no evidence of biological or clinical response.

What Happens if a JAK Inhibitor Is Stopped?

Alopecia areata is a chronic autoimmune disease, and JAK inhibitors do not permanently remove the underlying susceptibility.

The strongest randomized withdrawal evidence currently comes from baricitinib. Patients who had achieved meaningful regrowth after one year were randomized either to continue treatment or switch to placebo. By approximately three years, about 80 percent of those who had stopped baricitinib had lost treatment benefit compared with about 7 percent of those who continued treatment.

Many patients who lost hair after withdrawal regained response when baricitinib was restarted. In the available follow up, approximately 63 percent of evaluable patients originally receiving 2 mg and approximately 88 percent originally receiving 4 mg regained a SALT score of 20 or less after retreatment.

Not every patient regained response immediately, and withdrawal behavior has not been studied equally well for every JAK inhibitor.

The larger point is clear. JAK inhibitors should generally be viewed as disease controlling treatments rather than permanent cures.

Are JAK Inhibitors Used for Small Patches of Alopecia Areata?

Usually not as the first approach.

For a patient with one or several limited patches of alopecia areata, intralesional corticosteroid injections or potent topical corticosteroids may provide effective local treatment without exposing the entire body to systemic immune modulation.

Current guidelines give oral JAK inhibitors their clearest role in severe alopecia areata. There can be exceptions based on rapid progression, inability to use local therapy, repeated severe relapse or the overall burden of disease, but the existence of an FDA approved systemic treatment does not mean every person with alopecia areata needs systemic treatment.

What Are the Most Common Side Effects?

The routine adverse effect profiles are not identical across the three medications.

Adverse effects reported with one or more of the approved JAK inhibitors in alopecia areata studies include upper respiratory infections, headache, acne, folliculitis, urinary tract infections, herpes zoster, elevated cholesterol or other lipid changes, increased creatine phosphokinase, fatigue, gastrointestinal symptoms and changes in blood cell counts or liver enzymes.

Baricitinib, ritlecitinib and deuruxolitinib each have their own pattern of commonly reported adverse reactions and laboratory abnormalities. A side effect commonly reported with one medication should not automatically be assumed to occur at the same frequency with the others.

Most adverse events observed in alopecia areata trials have been mild or moderate. That does not eliminate the possibility of uncommon serious complications.

Why Do JAK Inhibitors Have Boxed Warnings?

The current FDA labels for baricitinib, ritlecitinib and deuruxolitinib contain boxed warnings addressing serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis.

These warnings need to be understood accurately. A major part of the cardiovascular, cancer, thrombosis and mortality concern behind the JAK inhibitor class warning originated from a large postmarketing safety trial of another JAK inhibitor, tofacitinib, in patients with rheumatoid arthritis who were age 50 or older and had at least one cardiovascular risk factor.

That population is not the same as the generally younger population treated for alopecia areata. The magnitude of risk demonstrated in that rheumatoid arthritis population should therefore not automatically be assumed to apply identically to every otherwise healthy patient with alopecia areata.

At the same time, the warnings cannot simply be dismissed because the original signal came from another JAK inhibitor or another disease population. Serious infections, malignancies, cardiovascular events and thrombosis have occurred during JAK inhibitor treatment, and the current FDA warnings remain clinically relevant.

The appropriate interpretation lies between unnecessary alarm and false reassurance.

What Do the Long Term Alopecia Areata Safety Data Show?

The growing disease specific safety database is reassuring, but it is not unlimited.

Baricitinib has now accumulated nearly 2,800 patient years of exposure in the BRAVE alopecia areata development program, with individual treatment extending as long as approximately four years. Serious adverse events remained uncommon and no new safety signal emerged during the extended follow up.

Ritlecitinib has also accumulated longer term experience through approximately two years, with the overall safety profile remaining consistent with earlier studies.

These findings are important because they provide information directly from alopecia areata patients rather than relying entirely on older rheumatology populations.

However, several years of clinical trial follow up cannot establish the complete safety profile of medications that some patients may ultimately take for decades. Continued long term surveillance remains important.

What Is the Risk of Serious Infection?

JAK inhibitors alter immune signaling and can reduce the body’s ability to control certain infections. Serious bacterial, fungal, viral and opportunistic infections have been reported. Tuberculosis is a particular concern, which is why patients are evaluated for active and latent tuberculosis before treatment.

Viral reactivation can also occur, including herpes zoster. Viral hepatitis screening is part of pretreatment evaluation according to the individual drug’s prescribing information and clinical guidelines. Ritlecitinib labeling specifically states that initiation is not recommended in patients with hepatitis B or hepatitis C.

A patient with an active serious infection generally should not begin treatment until the infection has been appropriately evaluated and controlled. New fever, persistent cough, unusual shortness of breath, a painful shingles like rash or other significant infection symptoms during treatment deserve medical attention.

What About Cancer Risk?

The FDA boxed warnings include malignancy. The strongest comparative cancer signal behind the class warning came from the rheumatoid arthritis safety study involving tofacitinib, where malignancies occurred more frequently than with TNF inhibitor treatment. Lymphoma and lung cancer were among the concerns, and current or former smokers represented a particularly important risk group.

That evidence does not prove that an otherwise healthy young patient taking a JAK inhibitor for alopecia areata has the same cancer risk as an older rheumatoid arthritis patient with cardiovascular risk factors.

Cancer history, smoking history and individual risk factors still belong in the treatment decision. Nonmelanoma skin cancers have also been reported with JAK inhibitor treatment, and periodic skin examination is appropriate for patients at increased risk.

What About Heart Attack, Stroke and Blood Clots?

Major adverse cardiovascular events, including heart attack and stroke, and thrombotic events including deep vein thrombosis and pulmonary embolism are included in the boxed warnings.

Risk assessment becomes particularly important in patients who are older, smoke or previously smoked, have cardiovascular disease, have significant cardiovascular risk factors or have a history that increases the likelihood of thrombosis.

Thrombotic events have also occurred during individual JAK inhibitor development programs. New chest pain, sudden shortness of breath, one sided leg swelling, severe unexplained headache or sudden neurological symptoms require urgent medical evaluation.

What About Low Blood Sugar in People With Diabetes?

Current U.S. prescribing information for the approved JAK inhibitors now includes warnings about hypoglycemia in patients with diabetes.

Hypoglycemia, including severe hypoglycemia, has been reported after initiation of JAK inhibitor treatment. Patients with diabetes may need more frequent glucose monitoring after treatment begins and should contact their physician if they develop symptoms suggesting low blood sugar.

This does not mean JAK inhibitors routinely cause hypoglycemia in people without diabetes. It is a specific safety consideration for patients already being treated for diabetes.

Can JAK Inhibitors Cause Gastrointestinal Perforation?

Rare gastrointestinal perforations have been reported with some JAK inhibitors.

Current baricitinib and deuruxolitinib prescribing information specifically advises additional caution in patients who may be at increased risk, including those with a history of diverticulitis, and recommends prompt evaluation of new abdominal symptoms.

This is an uncommon complication and should not be exaggerated, but persistent new abdominal pain, fever or other concerning gastrointestinal symptoms should not be ignored.

What Testing Is Needed Before Treatment?

The exact pretreatment evaluation differs by drug, but several principles are common. Patients are generally evaluated for active and latent tuberculosis and screened for viral hepatitis. Blood counts are obtained because these medications can affect lymphocytes, neutrophils, hemoglobin or platelets. Liver enzymes, kidney function and lipid levels may also be relevant depending on the medication and the individual patient.

Vaccination status should be reviewed before therapy begins. Appropriate vaccinations should generally be brought up to date before treatment when possible, and live vaccines are avoided during therapy. Herpes zoster vaccination deserves particular consideration when appropriate for the patient’s age and medical situation.

Deuruxolitinib additionally requires CYP2C9 genotype assessment before treatment.

Does Everyone Need the Same Blood Tests?

No. Monitoring needs to be specific to the medication being prescribed rather than reduced to the vague instruction that a patient needs occasional blood work.

Baricitinib monitoring includes blood counts, liver enzymes and lipids. Lipid testing is recommended at approximately 12 weeks after treatment begins and thereafter according to clinical management. Kidney function is particularly important because dose modification is required with renal impairment, and baricitinib is not recommended for alopecia areata when estimated glomerular filtration rate is below 30 mL per minute per 1.73 square meters. It is also not recommended in severe hepatic impairment.

Ritlecitinib requires absolute lymphocyte count and platelet count before treatment and again approximately four weeks after initiation, followed by monitoring according to routine patient management. Liver enzymes are evaluated at baseline and subsequently as clinically appropriate. Ritlecitinib is not recommended in severe hepatic impairment, but it does not have the same renal dosing limitations as baricitinib.

Deuruxolitinib requires complete blood count and lipid evaluation before and during therapy as well as CYP2C9 genotype determination before treatment. It is not recommended in severe renal impairment or severe hepatic impairment.

These differences are another reason the medications should not be treated as interchangeable.

Why Is CYP2C9 Testing Required Before Deuruxolitinib?

Deuruxolitinib is metabolized substantially through the CYP2C9 enzyme. Genetic variants can markedly reduce CYP2C9 activity in some individuals, who are called poor metabolizers. In these patients, deuruxolitinib concentrations can become substantially higher than intended and may increase the risk of serious adverse effects.

Current FDA labeling therefore requires CYP2C9 genotype determination before treatment and contraindicates deuruxolitinib in poor metabolizers. The drug is also contraindicated in patients taking moderate or strong CYP2C9 inhibitors.

An FDA cleared or FDA approved test specifically intended to direct Leqselvi use is not currently available. The absence of a dedicated FDA cleared companion test does not remove the requirement to determine CYP2C9 genotype before treatment.

Are There Important Drug Interactions?

Yes, and they differ by medication.

Strong OAT3 inhibitors such as probenecid can increase baricitinib exposure and may require dose modification.

Ritlecitinib can increase exposure to certain CYP3A and CYP1A2 substrates and should not be combined with strong CYP3A inducers that can substantially reduce ritlecitinib exposure.

Deuruxolitinib has especially important CYP2C9 interactions. Moderate or strong CYP2C9 inhibitors are contraindicated, while strong CYP3A4 and moderate or strong CYP2C9 inducers should be avoided because they can substantially reduce drug exposure.

Patients should provide the prescriber with a complete list of prescription medications, over the counter drugs, vitamins and supplements before treatment begins.

Can JAK Inhibitors Be Combined With Each Other?

They should not routinely be combined. Current prescribing information advises against using these medications together with other JAK inhibitors and generally advises against combination with biologic immune modulators, cyclosporine or other potent systemic immunosuppressants.

More immune suppression does not automatically produce more hair growth. It can increase risk.

Can Minoxidil Be Used With a JAK Inhibitor?

Minoxidil is sometimes used as an adjunct in clinical practice. The rationale is different from the JAK inhibitor itself. The JAK inhibitor addresses autoimmune signaling, while minoxidil may support hair growth once follicles begin returning to an active growth state.

Current alopecia areata guidelines acknowledge adjunctive topical or oral minoxidil in selected patients, but high quality evidence proving that minoxidil materially increases response to a JAK inhibitor remains limited.

It should therefore be described as adjunctive clinical practice rather than an established requirement.

What About Topical JAK Inhibitors?

Topical JAK inhibition has been studied for alopecia areata, including topical formulations of medications such as ruxolitinib and tofacitinib. The evidence has been considerably less convincing than the evidence for oral JAK inhibition.

Current alopecia areata guidelines consider the evidence insufficient to recommend topical JAK inhibitors as established treatment. The success of oral JAK inhibitors should therefore not be used to imply that applying a JAK inhibitor to the scalp will produce the same result.

Systemic and topical delivery are not interchangeable.

What About Tofacitinib and Other Off Label JAK Inhibitors?

Before FDA approved alopecia areata medications became available, drugs such as tofacitinib and ruxolitinib played an important role in establishing the therapeutic potential of JAK inhibition. Case series and observational studies demonstrated dramatic regrowth in some patients and helped drive development of medications that were later formally studied and approved for alopecia areata.

Tofacitinib and several other JAK inhibitors remain not FDA approved for alopecia areata in the United States.

Historical or off label experience should not be treated as equivalent to completion of large alopecia areata development programs and formal FDA approval for the condition.

What About Upadacitinib, Rinvoq?

Upadacitinib represents an important newer development.

Rinvoq is now authorized in the European Union for severe alopecia areata in adults and adolescents age 12 and older following Phase III development in the condition.

As of September 2026, upadacitinib is not FDA approved for alopecia areata in the United States.

This distinction matters because consumers increasingly encounter treatment information from international websites, social media and physicians practicing under different regulatory systems. An approval in Europe should not be described as an FDA approval in the United States.

What About Pregnancy?

JAK inhibitors used for alopecia areata should generally be avoided during pregnancy. Human pregnancy data remain limited, and animal reproductive studies have raised concerns about fetal harm with the currently approved medications.

Women who are pregnant, planning pregnancy or could become pregnant should discuss reproductive planning with the prescribing physician before treatment. The specific prescribing information for the medication being considered should be followed rather than assigning one universal JAK inhibitor washout interval to every drug.

What About Breastfeeding?

Breastfeeding is not recommended during treatment with the currently approved oral JAK inhibitors for alopecia areata, but the recommended period after the last dose differs considerably by drug.

Current U.S. prescribing information advises avoiding breastfeeding during treatment and for four days after the last dose of baricitinib, approximately 14 hours after the last dose of ritlecitinib and one day after the last dose of deuruxolitinib.

This is another practical example of why the medications should not simply be treated as interchangeable members of one class.

Can JAK Inhibitors Be Used in Older Adults?

They can be considered, but risk assessment becomes increasingly important with age. Older adults are more likely to have cardiovascular disease, thrombotic risk factors, previous malignancy, reduced kidney or liver function and multiple medications that may interact with treatment.

Current regulatory guidance places particular emphasis on careful consideration in older patients and in people with cardiovascular or cancer risk factors. Alopecia areata can be psychologically devastating at any age, but the risk benefit calculation for systemic immune modulation can look very different in a healthy 22 year old than in a 72 year old smoker with cardiovascular disease.

Can JAK Inhibitors Be Used in Children?

Ritlecitinib is FDA approved for severe alopecia areata beginning at age 12, while baricitinib and deuruxolitinib are currently approved for alopecia areata only in adults in the United States. Children younger than 12 require a different treatment discussion, and the presence of severe hair loss in a child does not justify simply adapting an adult JAK inhibitor regimen. Diagnosis, disease severity, development, vaccination status, infection risk and long term safety all require specialist consideration.

Do JAK Inhibitors Cure Alopecia Areata?

No. JAK inhibitors can suppress the immune signaling that drives alopecia areata and allow substantial hair regrowth, sometimes including near complete restoration of scalp, eyebrow and eyelash hair. They do not permanently remove the underlying autoimmune susceptibility.

Relapse after treatment withdrawal is common. That distinction matters enormously when a patient is deciding whether to begin treatment that may need to continue for years. The question is not simply whether hair can grow back. It is whether the benefit can be maintained with an acceptable long term balance of efficacy, safety, monitoring, cost and quality of life.

Who Should Be Especially Cautious With JAK Inhibitors?

Additional caution is appropriate in patients with a history of serious or recurrent infection, tuberculosis exposure, significant cardiovascular disease, previous blood clots, current or past smoking, malignancy, significant immune suppression, substantial kidney or liver disease, diabetes or medications that interact with the specific JAK inhibitor being considered. Risk also changes with age.

This does not mean that every risk factor automatically prohibits treatment. It means the decision should be individualized rather than treating JAK inhibitors as ordinary cosmetic hair medications.

What Should Be Evaluated Before Starting Treatment?

The diagnosis should be secure. Severe diffuse hair loss can sometimes be confused with other conditions, and systemic immune therapy should not be started merely because someone has lost a large amount of hair. The extent of scalp, eyebrow and eyelash loss should be documented objectively, ideally using standardized photography and SALT scoring.

The medical history should include infection history, tuberculosis risk, hepatitis status, vaccination history, smoking, cardiovascular disease, thrombotic history, cancer history, diabetes, current medications, reproductive plans and relevant kidney or liver disease. Baseline laboratory testing and any medication specific evaluations should be completed before treatment. This creates a meaningful baseline against which both efficacy and safety can be monitored.

What Should Someone Ask Before Starting a JAK Inhibitor?

A patient should understand why systemic treatment is being recommended, which specific drug is being proposed and why that medication makes sense for the individual’s age, disease severity and medical history. It is also reasonable to ask how response will be measured, how long treatment will be continued before it is judged unsuccessful, what laboratory monitoring will be required, what infections or symptoms should prompt a call to the physician, whether vaccinations should be updated, what happens if treatment is interrupted and what the long term plan will be if substantial regrowth occurs.

The decision should not be reduced to choosing whichever JAK inhibitor has the most impressive before and after photographs or whichever drug appears to have the highest response percentage in a different company’s clinical trial.

The AHLA Perspective

JAK inhibitors represent one of the most important advances ever made in the treatment of severe alopecia areata. For patients who historically had little realistic hope of recovering substantial scalp hair, eyebrows or eyelashes, these medications have demonstrated that major regrowth is possible. That deserves to be recognized.

It is equally important not to turn that progress into another form of hair loss marketing. These medications do not work for everyone. They are not cures. Response can take many months, and some patients require more than a year before reaching their best result. Relapse after discontinuation is common, which means treatment may become a long term commitment.

The currently approved medications should also not be treated as interchangeable simply because they are grouped under the term JAK inhibitor. They have different kinase profiles, age approvals, doses, interactions and monitoring requirements. Deuruxolitinib requires CYP2C9 genetic assessment. Baricitinib has dose reduction language once adequate control is achieved, although long term evidence shows that some patients lose response when the dose is reduced. Ritlecitinib is currently the only FDA approved option in this category for adolescents beginning at age 12.

The boxed warnings deserve context rather than either exaggeration or dismissal. Much of the cardiovascular, cancer, thrombosis and mortality signal behind the class warning came from an older rheumatoid arthritis population treated with another JAK inhibitor. That population is not identical to the typical alopecia areata patient. At the same time, the warnings remain clinically relevant, and serious risks cannot be dismissed simply because the disease being treated is hair loss.

The growing long term alopecia areata safety data are reassuring, but they still represent only the first several years of experience with treatments that some patients may ultimately use for decades.

For limited patchy alopecia areata, local treatment can still make considerably more sense than systemic immune modulation. For severe disease, JAK inhibition has changed the conversation completely.

The objective should be to establish the diagnosis, accurately define disease severity, evaluate the patient’s individual medical risk, choose the most appropriate treatment rather than the medication that sounds most potent, document response objectively and use the lowest effective sustainable exposure that maintains meaningful disease control with acceptable safety.

Used for: Alopecia Areata

Selected References

1. U.S. National Library of Medicine. Olumiant, Baricitinib Tablets: Full Prescribing Information. Includes FDA approved use for severe alopecia areata, dosing, boxed warnings, laboratory monitoring, renal considerations, hypoglycemia warning, pregnancy, lactation and drug interactions. DailyMed Prescribing Information
2. U.S. National Library of Medicine. Litfulo, Ritlecitinib Capsules: Full Prescribing Information. Includes FDA approved use for severe alopecia areata in adults and adolescents age 12 and older, boxed warnings, laboratory monitoring, treatment interruption, vaccination guidance, hypoglycemia warning and drug interactions. DailyMed Prescribing Information
3. U.S. National Library of Medicine. Leqselvi, Deuruxolitinib Tablets: Full Prescribing Information. Includes FDA approved use for severe alopecia areata, CYP2C9 genotype requirements, contraindications, boxed warnings, laboratory monitoring, gastrointestinal perforation, hypoglycemia and drug interactions. DailyMed Prescribing Information
4. King B, Ohyama M, Kwon O, et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. New England Journal of Medicine. 2022;386:1687 to 1699. doi:10.1056/NEJMoa2110343. PubMed
5. King B, Zhang X, Gubelin Harcha W, et al. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double Blind, Multicentre, Phase 2b to 3 Trial. The Lancet. 2023;401:1518 to 1529. doi:10.1016/S0140-6736(23)00222-2. PubMed
6. King B, Senna MM, Mesinkovska NA, et al. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults With Alopecia Areata: Results From the Phase 3 THRIVE AA1 Trial. Journal of the American Academy of Dermatology. 2024;91:880 to 888. doi:10.1016/j.jaad.2024.06.097. PubMed
7. Harries MJ, Ahmed A, Ascott A, et al. British Association of Dermatologists Living Guideline for Managing People With Alopecia Areata 2025. British Journal of Dermatology. 2026;194:e56 to e73. doi:10.1093/bjd/ljaf452. British Journal of Dermatology
8. King B, Ko J, Kwon O, et al. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE AA1 Randomized Clinical Trial. JAMA Dermatology. 2024;160:1075 to 1081. doi:10.1001/jamadermatol.2024.2734. PubMed
9. Piliang M, et al. Efficacy and Safety of Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb and III and Long Term Phase III Clinical Studies in Alopecia Areata. British Journal of Dermatology. 2025. PubMed
10. European Medicines Agency. Rinvoq, Upadacitinib. European authorization information includes severe alopecia areata in adults and adolescents age 12 and older. EMA